Background-We have shown that glucagon-like peptide-1 (GLP-1 amide) stimulates myocardial glucose uptake in dilated cardiomyopathy (DCM) independent of an insulinotropic effect. The cellular mechanisms of GLP-1-induced myocardial glucose uptake are unknown. Methods and Results-Myocardial substrates and glucoregulatory hormones were measured in conscious, chronically instrumented dogs at control (nϭ6), DCM (nϭ9) and DCM after treatment with a 48-hour infusion of GLP-1 (7-36) amide (nϭ9) or vehicle (nϭ6). GLP-1 receptors and cellular pathways implicated in myocardial glucose uptake were measured in sarcolemmal membranes harvested from the 4 groups. GLP-1 stimulated myocardial glucose uptake (DCM: 20Ϯ7 nmol/min/g; DCMϩGLP-1: 61Ϯ12 nmol/min/g; Pϭ0.001) independent of increased plasma insulin levels. The GLP-1 receptors were upregulated in the sarcolemmal membranes (control: 98Ϯ2 density units; DCM: 256Ϯ58 density units; Pϭ0.046) and were expressed in their activated (65 kDa) form in DCM. The GLP-1-induced increases in myocardial glucose uptake did not involve adenylyl cyclase or Akt activation but was associated with marked increases in p38␣ MAP kinase activity (DCMϩvehicle: 97Ϯ22 pmol ATP/mg/min; DCMϩGLP-1: 170Ϯ36 pmol ATP/mg/min; Pϭ0.051), induction of nitric oxide synthase 2 (DCMϩvehicle: 151Ϯ13 density units; DCMϩGLP-1: 306Ϯ12 density units; Pϭ0.001), and GLUT-1 translocation (DCMϩvehicle: 21Ϯ3% membrane bound; DCMϩGLP-1: 39Ϯ3% membrane bound; Pϭ0.005). The effects of GLP-1 on myocardial glucose uptake were blocked by pretreatment with the p38␣ MAP kinase inhibitor or the nonspecific nitric oxide synthase inhibitor nitro-L-arginine. Conclusions-GLP-1 stimulates myocardial glucose uptake through a non-Akt-1-dependent mechanism by activating cellular pathways that have been identified in mediating chronic hibernation and the late phase of ischemic preconditioning. (Circ Heart Fail. 2010;3:512-521.)
G lucagon-like peptide-1 (GLP-1 amide) is a member of the proglucagon family of naturally occurring incretins released by L-cells in the intestine in response to nutrient ingestion. [1] [2] [3] The cellular signaling mechanisms have been studied extensively in ␤-cells of the pancreas that serve
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as the principle physiological target, stimulating insulin release. 4, 5 However, recent investigation has focused on other extrapancreatic targets of GLP-1 action including direct effects on skeletal and cardiac muscle to stimulate glucose uptake, independent of its insulinotropic effects. 6 -9 Several laboratories have demonstrated GLP-1 transcripts in hearts of rodents 10 and humans, 11 and recently GLP-1 receptors were localized to cardiomyocytes and coronary endothelial cells in mouse hearts. 12 Our laboratory has demonstrated that dilated cardiomyopathy (DCM) in conscious dogs is associated with the development of insulin resistance 13 and that the impaired insulin actions are most evident on myocardial glucose uptake and coronary blood flow, as opposed to whole-body glucose disposition. We have observed the GLP-1 amide stimulates myocardial glucose uptake in conscious dogs with DCM 14 and in isolated normal and postischemic rat hearts. 15 Despite the emergence of evidence to support direct cardiac effects, 16 the mechanism of myocardial cellular effects of GLP-1 to stimulate myocardial glucose uptake and induce cardioprotection in large-animal models of nonischemic cardiomyopathy remains unknown.
Accordingly, the purpose of the present study was to determine the presence of GLP-1 receptors in the canine myocardium and whether the receptors are downregulated in heart failure. A second goal was to determine the mechanisms whereby GLP-1 increases myocardial glucose uptake and specifically whether these mechanisms involved increased Akt phosphorylation and GLUT-4 translocation as is true for classic myocardial insulin signaling. A third goal was to determine whether myocardial glucose uptake induced by GLP-1could be attenuated by inhibition of identified steps in the signaling cascade.
Methods Instrumentation
Forty-two mongrel dogs of either sex weighing 15 to 20 kg were instrumented as described previously from our laboratory. 13, 14 The dogs were allowed to recover from the surgical procedure for 2 weeks, during which time they were trained to lie quietly on the experimental table in a conscious, unrestrained state. Hemodynamic measurements were made with the dogs fully awake, lying quietly on their right side.
Hemodynamic Measurements
Baseline experiments consisted of left ventricular (LV) and systemic hemodynamic recordings to determine LV contractility (LV dP/dt), stroke volume, cardiac output (CO), and coronary blood flow (CBF). Six dogs did not undergo pacing and served as normal controls. DCM was induced by rapid right ventricular pacing (240 min Ϫ1 ) for 28 days in 36 dogs, as described previously. 13, 14 At that time, LV and systemic hemodynamics were measured with pacing suspended for 30 minutes. At this point (DCM), 9 dogs were euthanized to determine the effects of DCM on specified cellular signaling components in myocardial tissue. In the remaining 15 dogs, pacing rates were reduced to 180 min Ϫ1 for 48 hours, during which time they were randomized to receive a continuous infusion of synthetic GLP-1(7-36) amide (2.5 pmol/kg/min) through the right atrial catheter (DCMϩGLP-1, nϭ9) or vehicle (saline 2.8 mLϩ0.2 mL plasma/d; DCMϩVeh, nϭ6). After the additional 48 hours, the infusions were continued while the pacemakers were deactivated for 4 hours before the final hemodynamic and metabolic determinations. GLP-1(7-36) amide was prepared as described previously. 14 To determine whether the effects of GLP-1 on myocardial glucose uptake were p38␣ MAP kinase-dependent, we studied an additional 6 dogs, chronically instrumented as described above, before and after 28 days of rapid pacing. Myocardial glucose uptake was measured at baseline and after a 6-hour infusion of GLP-1 before and after the administration of the p38␣ MAP kinase inhibitor SB 203580 (Calbiochem, 1 mg/kg IV) over 60 minutes.
To determine whether the effects of GLP-1 on myocardial glucose uptake were nitric oxide (NO) dependent, we studied an additional 6 dogs, chronically instrumented as described above, before and after 28 days of rapid pacing. Myocardial NO uptake was measured at baseline and after a 6-hour infusion of GLP-1 before and after the administration of the nonspecific NO inhibitor nitro-L-arginine (N-LA) 30 mg/kg IV) over 30 minutes. The CBF response to intravenous acetylcholine injection (5 g/kg) was measured before and after N-LA administration to establish NO inhibition.
Metabolic Determinations
All dogs were fed a standard diet with fixed carbohydrate and fat content. Body weights were monitored weekly. Metabolic parameters were measured at 8 AM, after an overnight fast. Arterial and coronary sinus blood samples were obtained in all dogs at control and 28 days after initiation of rapid pacing. Transmyocardial substrate balance was calculated as the difference between arterial and coronary sinus content. Basal myocardial substrate uptake was calculated as the product of myocardial substrate balance and CBF, normalized for LV mass (expressed as nmol/min/g LV myocardium). Plasma glucose, nonesterified fatty acids, and NO levels were measured as described previously. 13, 14, 20 Myocardial insulin sensitivity was assessed in (a) baseline state (nϭ18), (b) after the development of DCM (day 28, nϭ9), and (c) after a 48-hour infusion of GLP-1 (day 30, nϭ9) or vehicle (day 30, nϭ6), using the hyperinsulinemiceuglycemic clamp technique as described previously. [12] [13] [14] 
Cellular Mechanisms
After the completion of the final clamp studies, GLP-1 or vehicle was continued for an additional 120 minutes, after which time the animals were anesthetized and intubated. LV samples were taken from the heart and sarcolemmal membrane preparations developed as described previously. 13, 15 GLP-1 receptors were measured in crude sarcolemmal membrane preparations using a rabbit polyclonal antibody (Alpha Diag International, San Antonio, Tex), as described previously. 13, 15 Goat anti-rabbit IgG-horseradish peroxidase conjugate, anti-Akt-1, and antiphospho-Akt-1 (Ser-473) were purchased from BD Transduction Laboratories (San Diego, Calif). PhosphoAkt-1 specificity was confirmed using phosphorylated and nonphosphorylated NIH/3T3 cell extracts purchased from Cell Signaling Technology, Inc (Beverly, Mass).
For the measurement of GLUT translocation, purified light (sarcolemmal) and heavy (intracellular) membrane vesicles and cytosolic fractions were isolated from LV myocardium using a sucrose gradient. 15, 21 Membranes were probed with rabbit anti-GLUT-4 and anti-GLUT-1 polyclonal antibody (1:1000) (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) overnight at 4°C. Densitometric analysis of the bands was carried out using a Personal Densitometer SI and ImageQuaNT Software (Molecular Dynamics, Sunnyvale, Calif) and expressed as the percentage of sarcolemmal membrane bound to total GLUT in LV homogenates. 15 The AMP-activated protein kinase activity in the LV myocardium was determined as described previously. 15 Activity was expressed as incorporated ATP (picomoles) per milligram of protein per minute. Total p38␣ MAP kinase (Santa Cruz Biotechnology, Santa Cruz, Calif) was assayed by Western blot and p38 MAP kinase activity was measured using an approach that measures the transfer of phosphate from ATP to targets of p38. NO synthase (NOS) isoforms were measured using antibodies purchased from Santa Cruz Biotechnology.
Adenylyl cyclase activity was assayed as described previously from our laboratory using this canine model. 22 was added to each tube to terminate the reaction, and the tubes were heated on a dry bath at 100°C for 3 minutes. cAMP was separated, as previously described. 22 
Mitochondrial Isolates
Crude mitochondrial isolates were prepared from canine myocardium using a trypsin digestion procedure as described previously. 23 The ) were subjected to electrophoretic separation by SDS-PAGE and quantified as described previously. 23 Reactive oxygen species were determined as a product of lipid peroxidation and measured as malondialdehyde using a commercially available assay from Cayman Chemicals (Ann Arbor, Mich).
Statistical Analysis
All measurements are expressed as meansϮSEM. The hemodynamic (Table 1 ) and metabolic (Table 2 ) responses to the vehicle or GLP-1 infusion were analyzed by repeated-measures ANOVA. Absolute P valves for the interaction of treatment effect with evolution of DCM were reported. The cellular signaling data in the 4 groups in Figure  1 to 6 were analyzed by 1-way ANOVA after a Levene test confirmed homogeneity of variances. Alternatively, a KruskalWallis test was used under circumstances in which variances were inhomogeneous. Differences in protein abundance and activity were compared between control and DCM or between DCMϩVeh and DCMϩGLP-1, using an unpaired Student t test. Table 1 illustrates the hemodynamic perturbations associated with the development of DCM in 15 dogs and the effects of infusion with vehicle or GLP-1 on hemodynamic recovery. At 28 days, the development of DCM was characterized by significant decreases in LV systolic pressure, LV dP/dt, CO, and LVEF, and significant increases in LV end-diastolic pressure, heart rate, CBF, and MVO 2 in both groups. GLP-1 infusion was associated with improvements in LV end-diastolic pressures (PϽ0.001), LV dP/dt (PϽ0.010), CO (PϽ0.007), and LV ejection fraction (PϽ0.002) compared with DCMϩVeh. Table 2 illustrates the effects of the development of GLP-1 treatment on plasma substrates and glucoregulatory hormones. Fasting plasma glucose and nonesterified fatty acids levels were normal in DCM and remained unchanged after treatment with vehicle or GLP-1. Both plasma insulin and glucagon levels increased during the development of DCM in both groups. However, plasma insulin levels (Pϭ0.005) and plasma glucagon levels (Pϭ0.0254) were reduced after GLP-1 treatment compared with the response in DCMϩVeh infusion. The salutary responses to GLP-1 treatment were associated with increases in plasma arterial NO levels (Pϭ0.046) and decreases in plasma norepinephrine levels (PϽ0.016) compared with DCMϩVeh infusion. Table 2 illustrates the results of the hyperinsulinemic-euglycemic clamps in the 2 treatment groups. GLP-1 infusion increased basal myocardial glucose uptake by 3-fold (DCMϩVeh: 22Ϯ6; DCMϩGLP-1: 61Ϯ12 nmol/min/g, PϽ0.001) in dogs with DCM. The GLP-1-induced increase in basal myocardial glucose uptake occurred despite lower basal insulin levels ( Table  2) . Insulin-stimulated myocardial glucose uptake during hyperinsulinemia was impaired significantly during the development of DCM in both treatment groups. However, GLP-1 infusion markedly augments insulin-stimulated myocardial glucose uptake (DCMϩVeh: 74Ϯ3 nmol/min/g; DCMϩGLP-1: 266Ϯ43 nmol/min/g; PϽ0.001) compared with DCϩVeh. Figure 1A reveals the expression of GLP-1 receptors in canine myocardium in all groups. The receptor was present in 2 isoforms. There was no difference in the 43-kDa isoform of the receptor among the groups. However, there was upregulation of the 65-kDa isoform in dogs with DCM compared with control (Pϭ0.046). There was no difference in GLP-1 receptor expression between vehicle-treated and GLP-1-treated groups. Figure 1B illustrates the effects of GLP-1 treatment on the adenylyl cyclase (AC) activity in sarcolemmal membrane preparations harvested from 6 control dogs, 6 dogs with DCM, 6 dogs with DCMϩVeh, and 6 dogs with DCMϩGLP-1. DCM was associated with decreased basal and agonist stimulated AC activity compared with control, consistent with heterologous desensitization. There was no significant impact of GLP-1 treatment on basal or stimulated AC activity. In separate experiments, sarcolemmal membranes incubated with increasing concentrations of GLP-1 (0.06 to 12 pmol/g protein) had no significant effect to stimulate cAMP generation (122 to 150 pmol/min/g protein), in contrast to other conventional agonists such as dobutamine, which increased cAMP production 5-fold (98 to 546 pmol/min/g protein, PϽ0.001). Thus, in contrast to what has been observed in pancreatic ␤-cells, GLP-1 had no measurable effects on AC activity in myocardium either in vivo or in vitro.
Results

Effects of GLP-1 on LV and Systemic Hemodynamics
The Effects of GLP-1 on Akt Activation
GLP-1 Receptors and Adenylyl Cyclase Activity in Canine Myocardium
Effects of GLP-1 on Akt Activation and Membrane Expression of GLUT Transporters
To determine whether GLP-1 increased myocardial glucose uptake through the PI3-kinase/Akt activation, we examined the phosphorylation of Akt in the 4 groups (Figure 2 ). There was no difference in Akt abundance, but there was significant reduction in Akt phosphorylation at serine 473 among groups (PϽ0.001). Specifically, there was a significant reduction in Akt phosphorylation between control and DCM (PϽ0.003) but no difference between vehicle-treated and GLP-1-treated dogs (Pϭ0.1042). Figure 3 illustrates the effects of GLP-1 treatment on GLUT expression in purified sarcolemmal membranes as a percentage of total GLUT expression. There was no difference in GLUT-4 expression in the various cellular compartments or in the percentage of membrane bound among the 4 groups ( Figure 3A , Pϭ0.5643). However, there was a significant increase in GLUT-1 expression in purified sarcolemmal membranes after GLP-1 treatment (Figure 3B, PϽ0.001) . Specifically, although there was no difference in GLUT-1 expression between control and DCM (Pϭ0.4809), there was a significant increase in GLUT-1 membrane expression in GLP-1-treated dogs compared with vehicle (PϽ0.01). Supplement Figure 3 illustrates the changes in the expression of GLUT 1 transporters in LV homogenates as well as cytosolic, intracellular, and sarcolemmal compartments. GLP-1 treatment was associated with small increases in GLUT-1 expression in LV homogenates and intracellular vesicles but not in cytosolic fractions. To examine the role of non-Akt-dependent mechanisms, we measured AMP kinase abundance and activity in the respective groups (Figure 4 ). There was no difference in protein expression ( Figure 4A were differences in p38␣ MAP kinase activity among the groups ( Figure 5B ). Specifically, GLP-1 treatment was associated with increased p38␣ MAP kinase activity (PϽ0.04) compared with the response in vehicle-treated dogs. Figure 6 shows the impact of GLP-1 infusion in DCM on the expression of NOS isoforms. There was no difference in NOS 3 isoform expression, but there was a doubling of NOS 2 expression in the dogs with DCM during GLP-1 infusion compared with vehicle infusion (PϽ0.001). Notably, DCM was associated with increased NOS 1 expression compared with control (PϽ0.004), which was maintained but not enhanced by GLP-1 ( Figure 6A ). The altered NOS isoform expression was associated with an increase in arterial NO concentrations (PϽ0.05, Table 2 ) and myocardial NO uptake in dogs with DCMϩGLP-1 compared with DCMϩVeh (PϽ0.001, Figure 6B ).
The Effects of GLP-1 on GLUT Translocation
Control
Effects of p38 MAP Kinase and NO Inhibition on GLP-1-Induced Myocardial Glucose Uptake
To determine whether the increases in p38 MAP kinase activity and NOS 2 expression were linked to the GLP-1-induced increases in myocardial glucose uptake, we conducted acute 6-hour infusions of GLP-1 in the presence and absence of acute pharmacological blockade of these pathways. Figure 7 illustrates the effects of inhibition of p38 MAP kinase ( Figure 7A, nϭ6) and nonspecific NOS inhibition with N-LA ( Figure 7B, nϭ6) on GLP-1-induced myocardial glucose uptake after an acute 6-hour infusion. Inhibition of p38 MAP kinase attenuated the GLP-1-induced increase in myocardial glucose uptake in both control dogs (PϽ0.01) and dogs with DCM (PϽ0.02). Pretreatment with N-LA markedly attenuated the GLP-1-induced increase in myocardial glucose uptake in both control (PϽ0.04) and DCM dogs (PϽ0.02). The effects were unrelated to differences in insulin levels or significant reductions in CBF but were associated with a decrease in glucose extraction. Figure 8 demonstrates the effects of a 48-hour infusion of GLP-1 on mitochondrial proteins and mitochondrial lipid peroxidation. DCM was associated with reductions in MCO-1, SDH, and UCP-3 expression (PϽ0.002). There was also a significant reduction in MnSOD expression. Neither MCO-1 nor SDH were altered by GLP-1 or vehicle infusion. However, GLP-1 significantly increased the expression of UCP-3 (PϽ0.02) and tended to increase MnSOD in DCM compared with vehicle (Pϭ0.0876, Figure 8A ). The development of DCM was associated with increased lipid peroxidation in whole-cell homogenates (PϽ0.02) and isolated mitochondria (PϽ0.001), and the levels were reduced after a 48-hour infusion of GLP-1 but not vehicle (PϽ0.01, Figure 8B ).
Effects of GLP-1 Infusion on Mitochondrial Function in DCM
Discussion
In the present study, we demonstrate that GLP-1 increases both basal and insulin-stimulated glucose uptake in the myocardium of conscious dogs with DCM. We demonstrated that the increase in myocardial glucose uptake was independent of Akt phosphorylation. Neither the improvement in myocardial function nor the increase in myocardial glucose uptake was associated with increased adenylyl cyclase activity. During DCM, AMP kinase activity was significantly increased in all groups, but the activity was sustained but not augmented by GLP-1 infusion. However, GLP-1 increased GLUT-1 expression in LV sarcolemmal membranes independent of any increase in plasma insulin levels and was associated with increases in p38␣ MAP kinase activity, increased expression of NOS 2 , and increased myocardial uptake of NO. GLP-1-induced increases in myocardial glucose uptake in the failing heart were attenuated by blockade of either p38 MAP kinase or NOS. Taken together, these data suggest that GLP-1 has direct effects on myocardial glucose uptake mediated through a pathway distinct from classic insulin-mediated glucose uptake.
Prior studies have demonstrated the presence of the GLP-1 receptor in the myocardium, 10 -12 but ours is the first study to our knowledge to demonstrate an increase in GLP-1 receptor in DCM. The 65-kDa isoform is considered to represent the glycosylated and active form 17 of the G-protein-coupled receptor and was increased in DCM and remained increased in DCMϩGLP-1-treated groups. The presence of the receptor supports the notion that GLP-1 may subtend physiological functions over and above those associated with its role in pancreatic insulin release.
We observed that GLP-1 infusion did not increase myocardial AC activity in control or DCM dogs, in contrast to what has been reported in ␤ cells. [3] [4] [5] Our findings are in keeping with recent observations in extrapancreatic tissues, where the actions of GLP-1 are unassociated with cAMP generation. 8, 9 The difference in pancreatic and extrapancreatic responses to GLP-1 may reflect differences in the expression of specific isoforms of AC or receptor coupling. Notably, AC type VIII predominates in the ␤-cell, 24, 25 whereas type V/VI is the predominant isoform in the heart. 26 Notably, there may be important species differences in protein sequences in the third intracellular loop of the GLP-1 receptor that govern coupling to specific Gs or Gi proteins. 27, 28 The significant improvement in LV function after 48-hour infusion of GLP-1 raises the possibility that these salutary improvements could be mediated through ␤-adrenergic mechanisms. There are several lines of evidence that argue against this possibility. First, the failure to increase cAMP argues against a conventional ␤ 1 -adrenergic mechanism. Second, GLP-1 infusion was associated with decreases in plasma norepinephrine, indicating that GLP-1 does not act by increasing sympathetic nervous system activation ( Table 2 ). Third, we have shown previously that acute GLP-1 infusion at doses of 1 to 20 pmol/kg/min does not increase heart rate or LV dp/dt in conscious dogs under control or after the development of DCM, in contrast to the response to dobutamine. 14 Finally, we have also shown previously that there is a temporal dissociation between the GLP-1 mediated increases in myocardial glucose uptake that occur within 3 to 6 hours of GLP-1 infusion and GLP-1-associated increases in contractility, which occur only after 12 to 24 hours of GLP-1 infusion (see Supplemental Materials). This temporal dissociation indicates a distinct process from that associated with ␤-adrenergic stimulation. Taken together, these data suggest that the hemodynamic improvements are not adrenergically mediated.
Alternative signaling mechanisms include the fact that GLP-1 has been shown to couple through its receptor on pancreatic ␤-cells via a G i ␣2, p38 MAP kinase-dependent mechanism. 19 p38 MAP kinase activation is a potent stimulus to NOS 2 activity and has been implicated as a mechanism involved in both chronic myocardial hibernation and the late phase of ischemic preconditioning. 29 Our laboratory has shown previously that GLP-1 enhanced myocardial recovery after both brief periods of coronary artery occlusion and reperfusion in both conscious dogs 30 and isolated rat hearts 15 as well as in dogs with DCM induced by rapid pacing. 14 We have also demonstrated that rapid pacing induces a state of chronic myocardial stunning in conscious dogs. 31 Our data suggest that this alternative pathway is activated in response to GLP-1 infusion in DCM.
Prior studies have demonstrated that GLP-1 inhibits gut motility in an NO-dependent fashion 32 and relaxes pulmonary 33 but not coronary vessels 34 in an NO-dependent fashion. NO has been established to play a critical role in contraction-dependent glucose uptake by stimulation of both GLUT-1 35 and GLUT-4 translocation 36 as well as vascular effects in isolated mouse heart preparations. 12 In our study, increased NOS 2 expression and increased myocardial NO production was observed in association with increased p38 MAP kinase activity and sarcolemmal GLUT-1 expression after GLP-1 infusion. p38 MAP kinase activation has also been associated with GLUT-1 translocation. 37, 38 These events were in turn associated with increased myocardial glucose uptake, independent of increased plasma insulin levels or Akt-1 activation. We showed that both p38 MAP kinase inhibition and nonspecific NOS inhibition independently blocked the GLP-1-induced increase in myocardial glucose uptake, implicating NO as a critical step in GLP-1-mediated glucose uptake in myocardium. However, we did not measure GLUT-1 expression after pharmacological blockade and therefore cannot conclude definitively that inhibition of p38 MAP kinase and NOS 2 limits GLUT-1 expression as the mechanism of altering myocardial glucose uptake.
GLP-1 treatment in DCM was also associated with changes in mitochondrial protein expression and reduced oxidative stress as assessed by lipid peroxidation. Specifically, UCP-3 activity has been shown to reduce reactive oxygen species production 39, 40 in mitochondria by contributing to decreased transmembrane potential (⌬). Increased oxidative stress has been associated with opening of the mitochondrial permeability transition, leading to mitochondrial swelling and ultimately rupture and necrosis. 39, 40 We have shown previously that DCM is associated with myocardial mitochondrial vacuolization and swelling consistent with MPT opening. 23 The GLP-1-associated increase in UCP-3 is consistent with the observed reduction in oxidative stress. We did observe that GLP-1 treatment was associated with a trend toward increased expression of MnSOD, suggesting that GLP-1 may affect other mitochondrial defense mechanisms against oxidative stress besides UCP-3. Further studies will be needed to understand the complete effects of GLP-1 on mitochondrial activity.
In conclusion, GLP-1 stimulates myocardial glucose uptake in conscious dogs with pacing-induced DCM through a p38␣ MAP kinase-mediated and NO-dependent mechanism. The effects are neither adenylyl cyclase-dependent nor Aktdependent in the heart of normal dogs or dogs with DCM. The availability of an alternative pathway to stimulate glucose uptake in the presence of insulin resistance holds therapeutic promise.
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